Hidden Nuclear Role of Metabolic Enzyme FAH Drives Breast Cancer Drug Resistance

One of the most frustrating patterns in modern oncology is the way breast cancers that respond beautifully to treatment at first can quietly learn to shrug it off. For patients with hormone receptor positive breast cancer, the most common subtype of the disease, the standard of care now includes a class of drugs called CDK4/6 inhibitors, which have transformed survival prospects by blocking two molecular engines that cancer cells depend on to divide. Yet a substantial share of patients eventually relapse on these drugs, and when resistance emerges, the options narrow and outcomes worsen. A new study from researchers at Boston Children’s Hospital and collaborators, published in Science Advances, offers a striking explanation for part of that failure, and it comes from an unexpected corner of cell biology.

The research team, co-led by Naama Kanarek of the Pathology Department at Boston Children’s Hospital and Taru Muranen, set out to understand the genetic and molecular drivers behind resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer. Their investigation converged on an enzyme with a well-established day job and, as it turns out, a previously hidden second career. The enzyme is fumarylacetoacetate hydrolase, or FAH, a protein long known to biochemists for its role in the breakdown of tyrosine, an amino acid obtained from the diet and from protein turnover. FAH catalyzes the final step of the tyrosine degradation pathway, a reaction that takes place in the cytosol, the fluid interior of the cell where most metabolic chemistry occurs.

That cytosolic identity is precisely what made the new finding so surprising. When the researchers examined breast cancer cells that had been treated with CDK4/6 inhibitors, they found FAH in a place it was never expected to be: the nucleus, the membrane-bound compartment that houses the genome and orchestrates gene expression. The accumulation of a metabolic enzyme in the nucleus of drug-treated cancer cells suggested that FAH was doing something far beyond amino acid catabolism. In recent years, cancer biologists have increasingly recognized that many metabolic enzymes moonlight as regulators of gene expression, transcription, and cell fate, and the new work adds FAH to that growing list of dual-function proteins.

The team did not stop at locating FAH in an unexpected compartment. They went on to dissect the molecular mechanism by which nuclear FAH confers resistance, and their findings point to a specific interaction with another critical regulator of the cell cycle. In the nucleus, FAH physically interacts with CDK9, a cyclin-dependent kinase that functions as a master regulator of cell fate and gene transcription. CDK9 is best known for its role in releasing RNA polymerase II from a paused state, allowing genes to be transcribed efficiently, and it has become an attractive drug target in its own right in several cancers. The researchers showed that FAH stimulates CDK9 activity, effectively giving the cancer cell’s transcriptional machinery a boost that helps it survive the assault of CDK4/6 inhibition.

The mechanistic story has a clear therapeutic punchline. When the team inhibited CDK9, the resistance conferred by FAH collapsed. In other words, blocking CDK9 reverses the FAH-mediated resistance that allows breast cancer cells to keep proliferating despite CDK4/6 inhibitor treatment. This is a crucial distinction from many resistance mechanisms, which are identified in cell culture but offer no obvious pharmacological handle. CDK9 inhibitors already exist and are being evaluated in clinical settings, which means the pathway from this laboratory discovery to a testable treatment strategy is unusually short.

Indeed, the authors suggest that CDK9 inhibition, whether used alone or in combination with CDK4/6 inhibitors, could represent an immediate and actionable clinical approach for mitigating relapse in hormone receptor positive breast cancer patients treated with CDK4/6 inhibitors. Combination therapy is an especially appealing concept because it could attack the cancer through two independent vulnerabilities at once: the CDK4/6 axis that drives cell cycle progression and the CDK9 axis that FAH exploits to sustain transcriptional programs needed for survival. Cancers that attempt to escape the first drug would be caught by the second, potentially delaying or preventing the emergence of fully resistant disease.

Beyond treatment, the discovery opens a promising avenue for early diagnosis. Because FAH relocates to the nucleus specifically in cells exposed to CDK4/6 inhibitors, nuclear FAH could serve as a biomarker of resistance, a visible molecular flag indicating that a patient’s tumor is beginning to adapt to therapy. Detecting resistance before the cancer has clinically relapsed is one of the central goals of precision oncology, since intervening early, when the tumor burden is still low and the resistant population is still small, is far more effective than reacting after widespread regrowth. A biomarker that can be assessed in tumor tissue could allow oncologists to monitor treatment response at the molecular level and adjust therapy accordingly.

The clinical context makes these findings consequential. Hormone receptor positive breast cancer accounts for the majority of breast cancer diagnoses, and CDK4/6 inhibitors, which include drugs that block the CDK4 and CDK6 kinases responsible for driving cells through a key checkpoint of the cell division cycle, have become a cornerstone of treatment for advanced disease. These inhibitors work by halting the transition from the growth phase of the cell cycle into DNA replication, effectively putting the brakes on proliferation. However, cancer cells are notoriously adaptable, and resistance to CDK4/6 inhibition develops in many patients over time, through mechanisms that remain incompletely understood. Each newly identified resistance pathway, such as the FAH-CDK9 axis described in this study, adds a piece to that puzzle and expands the repertoire of strategies clinicians can bring to bear against relapse.

The study also contributes to a broader conceptual shift in cancer biology. FAH is best known to the medical community in a very different context: inherited mutations in the FAH gene cause hereditary tyrosinemia type 1, a rare metabolic disease in which toxic intermediates of tyrosine breakdown accumulate in the body. That an enzyme celebrated for its metabolic role in the cytosol can also migrate to the nucleus, engage a transcriptional kinase, and rewire the response of cancer cells to targeted therapy underscores how fluid the functional boundaries of cellular proteins can be. The finding reinforces the idea that metabolic enzymes frequently possess non-canonical functions, and that these hidden activities may be particularly important under the selective pressures of cancer treatment, when cells are forced to improvise new survival strategies.

For patients and clinicians, the practical implications are twofold. First, nuclear FAH may allow earlier identification of tumors that are becoming resistant to CDK4/6 inhibitors, creating a window for therapeutic adjustment before relapse becomes established. Second, the demonstration that CDK9 inhibition reverses FAH-mediated resistance provides a rational basis for clinical trials of CDK9 inhibitors, alone or in combination with existing CDK4/6 inhibitors, in patients whose tumors show evidence of this resistance mechanism. The work, published in Science Advances under the title describing a non-canonical function of the tyrosine degradation enzyme FAH in CDK4/6 inhibitor resistance, represents the kind of translational insight that can move from a laboratory observation to a clinical strategy with unusual speed, precisely because the druggable target at the end of the pathway already has inhibitors in development. As resistance remains the central obstacle to durable responses in hormone receptor positive breast cancer, a newly discovered driver with a matching pharmacological answer is a development worth watching closely.

Subject of Research: A non-canonical nuclear function of the tyrosine degradation enzyme FAH that drives resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer

Article Title: New path to combat breast cancer’s resistance to therapy

Article References: New path to combat breast cancer’s resistance to therapy. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: breast cancer, CDK4/6 inhibitors, FAH, CDK9, drug resistance, hormone receptor positive, Science Advances, biomarker, nuclear enzyme, combination therapy, Boston Children's Hospital, tyrosine degradation